{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:29:25Z","timestamp":1777055365615,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40271-022-00614-7","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:02:55Z","timestamp":1673438575000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8263-4047","authenticated-orcid":false,"given":"Damon","family":"Willems","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Lotta","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hessel H.","family":"Van der Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-570X","authenticated-orcid":false,"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Mickael","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"issue":"13","key":"614_CR1","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(13):6709.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"614_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/01.ASW.0000831084.75243.66","volume":"35","author":"S Fisher","year":"2022","unstructured":"Fisher S, Ziv M. Interviewing women with hidradenitis suppurativa: thematic and content analysis. Adv Skin Wound Care. 2022;35(7):381\u20134.","journal-title":"Adv Skin Wound Care"},{"issue":"2","key":"614_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice: hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"614_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.15940","volume":"34","author":"N Kirsten","year":"2020","unstructured":"Kirsten N, Petersen J, Hagenstrom K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany: an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34(1):174\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"614_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"6","key":"614_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"614_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"614_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231(2):184\u201390.","journal-title":"Dermatology"},{"issue":"4","key":"614_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"614_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","volume":"81","author":"P Aarts","year":"2021","unstructured":"Aarts P, et al. Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa. Drugs. 2021;81(12):1397\u2013410.","journal-title":"Drugs"},{"key":"614_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram JR, Betolli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597\u2013605.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"614_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/jdv.17857","volume":"36","author":"R Kjaersgaard Andersen","year":"2022","unstructured":"Kjaersgaard Andersen R, et al. Incidence and remission rates of self-reported hidradenitis suppurativa: a prospective cohort study conducted in Danish blood donors. J Eur Acad Dermatol Venereol. 2022;36(5):717\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"614_CR13","doi-asserted-by":"crossref","unstructured":"De DR, Shih T, Fixsen D, et al. Biologic use in hidradenitis suppurativa: patient perspectives and barriers. J Dermatol Treat. 2022;33(7):1\u20134.","DOI":"10.1080\/09546634.2022.2089336"},{"issue":"7","key":"614_CR14","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms23073753","volume":"23","author":"A Markota Cagalj","year":"2022","unstructured":"Markota Cagalj A, Marinovic B, Bukvic MZ. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022;23(7):3753.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"614_CR15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/biomedicines10061303","volume":"10","author":"CH Huang","year":"2022","unstructured":"Huang CH, Huang IH, Tai CC, et al. Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta-analysis. Biomedicines. 2022;10(6):1303.","journal-title":"Biomedicines."},{"issue":"11","key":"614_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388.","journal-title":"JAMA Dermatol"},{"issue":"Suppl. 1","key":"614_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl. 1):8\u201317.","journal-title":"Exp Dermatol"},{"key":"614_CR18","unstructured":"Kimball A. Secukinumab in moderate-to-severe hidradenitis suppurativa: primary endpoint analysis from the SUNSHINE and SUNRISE phase III trials. In: Proceedings of the 31st European Academy of Dermatology and Venereology (EADV) congress, Milan, 2022. p. 7\u201310."},{"key":"614_CR19","unstructured":"Dermatology Times. UCB announces positive phase 3 studies for bimekizumab in hidradenitis suppurativa. 2022. https:\/\/www.dermatologytimes.com\/view\/ucb-announces-positive-phase-3-studies-for-bimekizumab-in-hidradenitis-suppurativa. Accessed 3 Jan 2023."},{"issue":"6","key":"614_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1468-3083.2012.04569.x","volume":"27","author":"N Umar","year":"2013","unstructured":"Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schollgen I, Terris DD. Matching physicians\u2019 treatment recommendations to patients\u2019 treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol. 2013;27(6):763\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"614_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-021-00539-7","volume":"15","author":"D Willems","year":"2022","unstructured":"Willems D, Hiligsmann M, van der Zee HH, Sayed CJ, Evers S. Identifying unmet care needs and important treatment attributes in the management of hidradenitis suppurativa: a qualitative interview study. Patient. 2022;15(2):207\u201318.","journal-title":"Patient"},{"issue":"2","key":"614_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","volume":"13","author":"JC Bouvy","year":"2020","unstructured":"Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145\u20139.","journal-title":"Patient"},{"issue":"10","key":"614_CR23","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","volume":"29","author":"MP Ho","year":"2015","unstructured":"Ho MP, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984\u201393.","journal-title":"Surg Endosc"},{"issue":"12","key":"614_CR24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1080\/13696998.2020.1840181","volume":"23","author":"D Willems","year":"2020","unstructured":"Willems D, Charokopou M, Evers S, Hiligsmann M. Early health economic modelling for a treatment candidate in hidradenitis suppurativa. J Med Econ. 2020;23(12):1516\u201324.","journal-title":"J Med Econ"},{"issue":"1","key":"614_CR25","first-page":"106","volume":"10","author":"T Jevtic","year":"2013","unstructured":"Jevtic T, Bukumiric Z, Jankovic SM. Effects of treatment adherence on clinical and economic outcomes in patients with psoriasis. Med Glas (Zenica). 2013;10(1):106\u201312.","journal-title":"Med Glas (Zenica)."},{"issue":"8","key":"614_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/03007995.2020.1776233","volume":"36","author":"N Sain","year":"2020","unstructured":"Sain N, Willems D, Charokopou M, Hiligsmann M. The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments. Curr Med Res Opin. 2020;36(8):1257\u201375.","journal-title":"Curr Med Res Opin"},{"key":"614_CR27","doi-asserted-by":"crossref","unstructured":"Gaspar K, Gergely HL, Jenei B, et al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study.Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):1\u201310.","DOI":"10.1080\/14737167.2021.1895753"},{"issue":"2","key":"614_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1468-3083.2011.04440.x","volume":"27","author":"ML Schaarschmidt","year":"2013","unstructured":"Schaarschmidt ML, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"614_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bjd.15086","volume":"176","author":"RJ Thorneloe","year":"2017","unstructured":"Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol. 2017;176(3):667\u201376.","journal-title":"Br J Dermatol"},{"issue":"3","key":"614_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/0272989X16683934","volume":"37","author":"C Vass","year":"2017","unstructured":"Vass C, Rigby D, Payne K. The role of qualitative research methods in discrete choice experiments. Med Decis Mak. 2017;37(3):298\u2013313.","journal-title":"Med Decis Mak"},{"issue":"5","key":"614_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"614_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10198-014-0614-4","volume":"16","author":"AC Muhlbacher","year":"2015","unstructured":"Muhlbacher AC, et al. Chronic pain patients\u2019 treatment preferences: a discrete-choice experiment. Eur J Health Econ. 2015;16(6):613\u201328.","journal-title":"Eur J Health Econ"},{"key":"614_CR33","doi-asserted-by":"crossref","unstructured":"Sumpton D, Kelly A, Craig JC, et al. Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment. Arthritis Care Res (Hoboken). 2022;74(8):1234\u201343.","DOI":"10.1002\/acr.24782"},{"issue":"2","key":"614_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369\u201378.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"614_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407\u201314.","journal-title":"J Pain"},{"issue":"4","key":"614_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0272989X19841877","volume":"39","author":"B Copsey","year":"2019","unstructured":"Copsey B, Buchanan J, Fitzpatrick R, Lamb SE, Dutton SJ, Cook JA. Duration of treatment effect should be considered in the design and interpretation of clinical trials: results of a discrete choice experiment. Med Decis Mak. 2019;39(4):461\u201373.","journal-title":"Med Decis Mak"},{"issue":"1","key":"614_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-9.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"614_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.19863","volume":"185","author":"LM Prens","year":"2021","unstructured":"Prens LM, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. Br J Dermatol. 2021;185(1):177\u201384.","journal-title":"Br J Dermatol"},{"key":"614_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","volume":"15","author":"L Quartuccio","year":"2019","unstructured":"Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2019;15:87\u201393.","journal-title":"J Adv Res"},{"issue":"8","key":"614_CR40","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368\u201376.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"614_CR41","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, Johnston AD, Kutner AJ, Micheletti AG, Hosgood HD, Cohen SR. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"614_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health."},{"issue":"1","key":"614_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health."},{"issue":"8","key":"614_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26(8):661\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"614_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183(2):340\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"614_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2340\/00015555-2129","volume":"96","author":"PT Riis","year":"2016","unstructured":"Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96(2):222\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"614_CR47","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11136-020-02732-x","volume":"30","author":"A Bato","year":"2021","unstructured":"Bato A, et al. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res. 2021;30(5):1477\u201390.","journal-title":"Qual Life Res"},{"issue":"10","key":"614_CR48","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jval.2018.04.1822","volume":"21","author":"T Tervonen","year":"2018","unstructured":"Tervonen T, Schmidt-Ott T, Marsh K, Bridges JFP, Quaife M, Janssen E. Assessing rationality in discrete choice experiments in health: an investigation into the use of dominance tests. Value Health. 2018;21(10):1192\u20137.","journal-title":"Value Health."},{"issue":"6","key":"614_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","volume":"17","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Marshall DA, Hauber AB, Bridges JFP. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):531\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"614_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373\u201384.","journal-title":"Patient"},{"issue":"4","key":"614_CR51","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315.","journal-title":"Value Health."},{"key":"614_CR52","doi-asserted-by":"crossref","unstructured":"Boeri M, Sutphin J, Hauber B, et al. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatol Treat. 2022;33(3):1449\u201358.","DOI":"10.1080\/09546634.2020.1832185"},{"issue":"2","key":"614_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40273-017-0575-4","volume":"36","author":"M Zhou","year":"2018","unstructured":"Zhou M, Thayer WM, Bridges JFP. Using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconomics. 2018;36(2):175\u201387.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"614_CR54","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642\u201350.","journal-title":"Br J Dermatol"},{"key":"614_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence. 2021;15:811\u201334.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"614_CR56","doi-asserted-by":"crossref","first-page":"238146831983792","DOI":"10.1177\/2381468319837925","volume":"4","author":"C Somers","year":"2019","unstructured":"Somers C, Chimonas S, McIntosh E, Kaltenboeck A, Briggs A, Bach P. Using nominal group technique to identify key attributes of oncology treatments for a discrete choice experiment. MDM Policy Pract. 2019;4(1):2381468319837925.","journal-title":"MDM Policy Pract."},{"key":"614_CR57","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1471-2474-14-160","volume":"14","author":"TL Laba","year":"2013","unstructured":"Laba TL, Brien JA, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013;14:160.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-022-00614-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-022-00614-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-022-00614-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:53:24Z","timestamp":1725616404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-022-00614-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40271-022-00614-7","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"15 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DW is a registered PhD student at Maastricht University and an employee of UCB Pharma, UCB Pharma had no role in the design, conduct, and analysis of the study, or in the writing\/reviewing of this manuscript. EH is a registered PhD student at Maastricht University and an employee of EY-Parthenon, EY-Parthenon had no role in the design, conduct, and analysis of the study, or in the writing\/reviewing of this manuscript. HZ received consultancy fees from Abbvie, InflaRX, Novartis, and Insmed. CS is a speaker for Abbvie and Novartis, a consultant for Abbvie, Novartis, UCB, InflaRx, and Alcaris, has received education grants from Abbvie, and has been an investigator with fees paid to his institution for Abbvie, Novartis, Incyte, InflaRx, Chemocentryx, and UCB. CS has an unpaid position on the board of the Hidradenitis Suppurativa Foundation. JRI received a stipend as Editor-in-Chief of the <i>British Journal of Dermatology<\/i> and an authorship honorarium from UpToDate. He is a consultant for Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, and UCB Pharma and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio. He is co-copyright holder of the HiSQOL Questionnaire, Investigator Global Assessment, and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument and related instruments. CB, SE, and MH have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Maastricht University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethics approval was granted by the Faculty of Health, Medicine and Life Sciences of Maastricht University on 3 January, 2022 (FHML-REC\/2021\/115).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The submission does not include personal details or images that may lead to the identification of participants and all participants gave consent to publish their anonymized data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maastricht University is committed to share the data that support the findings of this study with qualified external researchers. The requests are to be made to the corresponding author and will be appraised based on their scientific merit.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by DW, LH, CB, and MH. The manuscript was written by DW and all authors provided feedback throughout the development of the manuscript and read and approved the final manuscript. All authors sufficiently contributed to this research according to ICMJE criteria to qualify as a listed author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}